Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Inflammatory remodeling and CD4+ T cell expansion in TET2-mutated myeloid disorders

Kehan Ren, Ermin Li, Xu Han et al. Nov 03, 2025 pp. 3162-3162 10.1182/blood-2025-3162

Abstract Ten-eleven translocation 2 (TET2) encodes a DNA demethylation enzyme, and it is one of the most frequently mutated genes in myeloid...

Disparities in sickle cell disease related mortality in the US-Mexico border region from 1999 to 2020: A CDC wonder Study

Allahdad Khan, Fnu Namal, Kumail Ali et al. Nov 03, 2025 pp. 7974-7974 10.1182/blood-2025-7974

Abstract Background: Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a point mutation in the β-globin gene, resulting i...

A quality improvement project to optimize IVC filter use and retrieval: Translating guidelines into practice

Abdulrahman Al Raizah, Mohsen Al Zahrani, Ayman Hejazi et al. Nov 03, 2025 pp. 1070-1070 10.1182/blood-2025-1070

Abstract Introduction Inferior vena cava (IVC) filters are used to prevent pulmonary embolism (PE) in patients with venous thromboembolism (...

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Yulia Shifrin, Asieh Alikhah, Zahabiya Husain et al. Nov 03, 2025 pp. 2217-2217 10.1182/blood-2025-2217

Abstract Introduction: Novel therapeutic approaches, especially cellular therapies, have significantly prolonged the survival of patients wi...

Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma.

Jieyu Xu, Weihao Zhuang, Yangjie Ru et al. Nov 03, 2025 pp. 1874-1874 10.1182/blood-2025-1874

Abstract Introduction Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive and heterogeneous peripheral T-cell lymphoma derived from f...

A multicenter, randomized, open-label study of dexamethasone versus romiplostim plus dexamethasone as first line treatment in patients with newly diagnosed immune thrombocytopenia: Interim results of rodex study

Maria Eva Mingot, Monica Carpenedo, Mariana Canaro Hinryk et al. Nov 03, 2025 pp. 733-733 10.1182/blood-2025-733

Abstract Background: Corticosteroids remain the standard first-line treatment for immune thrombocytopenia (ITP), yet less than 40% of patien...

Targeting hemolysis and raas: Osivelotor and losartan ameliorate sickle cell renal pathology

Najmeh Eskandari, Suman Setty, Guohui Ren et al. Nov 03, 2025 pp. 1147-1147 10.1182/blood-2025-1147

Abstract In sickle cell disease (SCD), progressive renal dysfunction is common and driven by mechanisms such as chronic hemolysis, vascular...

Serum albumin, but not gnri, is an independent prognostic factor for survival after first allogeneic SCT: A large-scale multicenter analysis

Yasutaka Sadaga, Yuho Najima, Takayoshi Tachibana et al. Nov 03, 2025 pp. 2513-2513 10.1182/blood-2025-2513

Abstract Background: While we previously reported that the geriatric nutritional risk index (GNRI) is a strong independent prognostic factor...

Protac-mediated degradation of neutrophil elastase as a potential therapeutic strategy for ELANE-related neutropenia

Vahagn Makaryan, Merideth Kelley, Gobind Chugh et al. Nov 03, 2025 pp. 620-620 10.1182/blood-2025-620

Abstract Background: Mutations in ELANE are the most common cause of both cyclic and severe congenital neutropenia. ELAN...

A novel Janus kinase 1 and 2 inhibitor, baricitinib, for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation

Chen Zhao, Yuanyuan Zhang, Hai-Xia Fu et al. Nov 03, 2025 pp. 6015-6015 10.1182/blood-2025-6015

Abstract Introduction Allogeneic stem cell transplantation (allo-SCT) is an effective and straightforward therapy for hematology patients, a...

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Andrew Palmer, Alexa Schoen, Madelyn Burkart et al. Nov 03, 2025 pp. 2838-2838 10.1182/blood-2025-2838

Abstract Introduction: Disparate outcomes have been reported in patients (pts) with myeloproliferative neoplasms (MPNs), such as increased r...

Socioeconomic inequality in acute myeloid leukaemia treatment in England: What drives this inequality

Koki Shimizu, Mari Saito, Camille Maringe et al. Nov 03, 2025 pp. 6385-6385 10.1182/blood-2025-6385

Abstract Introduction: Socioeconomic inequalities in survival of acute myeloid leukaemia (AML) exist. In a private healthcare context such a...

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Suning Chen, Yu Wu, Jianyu Weng et al. Nov 03, 2025 pp. 1574-1574 10.1182/blood-2025-1574

Abstract Introduction Ph+ ALL is the most common genetic subtype of adult ALL, is associated with high relapse risk and poor outcomes, and i...

Activation of endogenous retroviral elements drives inflammation and transformation in STAG2-mutant myeloid malignancies

Johann-Christoph Jann, Ariel Swett, Yihua Wang et al. Nov 03, 2025 pp. 987-987 10.1182/blood-2025-987

Abstract Cohesin is a multimeric protein complex that regulates three-dimensional chromatin architecture and gene regulation. In myeloid mal...

Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features

Kyung Ju Ryu, Bon Park, Sang Eun Yoon et al. Nov 03, 2025 pp. 5311-5311 10.1182/blood-2025-5311

Abstract Background Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a distinct lymphoma subtype associated with Epstein-Barr virus...

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Jesus Gonzalez-Lugo, Alex Ambinder, Deedra Nicolet et al. Nov 03, 2025 pp. 294-294 10.1182/blood-2025-294

Abstract Background: MECOM-rearranged (MECOM-r) AML is a rare AML subtype that is characterized by the disease-defining inv(3)(q21q26.2), t(...

Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability

Xue Yang, Yuhong Ren, Luya Cheng et al. Nov 03, 2025 pp. 3682-3682 10.1182/blood-2025-3682

Abstract Introduction Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL) that predominant...

Clinical profiling and outcomes of ischemic stroke patients with immune thrombocytopenia: A multicenter real-world study

Liqin Cao, Jin Wu, Fan Zhou et al. Nov 03, 2025 pp. 1264-1264 10.1182/blood-2025-1264

Abstract Introduction Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by platelet destruction mediated by aut...

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Angel Serna, Gloria Iacoboni, Anna Aguilera Romero et al. Nov 03, 2025 pp. 3737-3737 10.1182/blood-2025-3737

Abstract Introduction Cytokine release syndrome (CRS) is a common toxicity observed during the step-up dosing of bispecific antibody (BsAb) t...

Anthropometric data from a large cohort of Indian sickle cell disease subjects.

Dinesh Pendharkar, Garima Nirmal Nov 03, 2025 pp. 6497-6497 10.1182/blood-2025-6497

Abstract Introduction Sickle cell disease (SCD) is the most common monogenic disorder in India and globally, contributing to non-communicabl...

Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients

Yingying Huo, Haixiao Zhang, Yebo Peng et al. Nov 03, 2025 pp. 769-769 10.1182/blood-2025-769

Abstract Targeted therapies have transformed the treatment landscape of hematological malignancies; however, meaningful progress for older/u...

Platelet mitofusin-1 mediates endothelial cell dysfunction in pulmonary arterial hypertension via the NLRP3 inflammasome and interleukin-1B

Mark Perfetto, Gowtham Annarapu, Andrea Jardini et al. Nov 03, 2025 pp. 422-422 10.1182/blood-2025-422

Abstract Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder driven by metabolic and endothelial cell dysfunction (E...

Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia

Zachary Graff, Amy Pan, Nathan Gossai et al. Nov 03, 2025 pp. 5244-5244 10.1182/blood-2025-5244

Abstract Background and Significance: Effective treatment for children with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains a...

Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM)

Azra Borogovac, Murali Janakiram, NI-Chun Tsai et al. Nov 03, 2025 pp. 405-405 10.1182/blood-2025-405

Abstract Background: Cilta-cel is an anti-B-Cell maturation antigen (BCMA) CAR T-cell therapy approved for RRMM. Manufacturing failure (MF)...

Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study by the italian association of pediatric hematology-oncology (AIEOP)

Nicolò Peccatori, Sofia Arnaboldi, Veronica Leoni et al. Nov 03, 2025 pp. 5095-5095 10.1182/blood-2025-5095

Abstract Background: High-dose methotrexate (HDMTX) is a key component of the treatment of pediatric acute lymphoblastic leukemia (ALL). Tho...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page